Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03222674
PHASE1/PHASE2

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Sponsor: Shenzhen Geno-Immune Medical Institute

View on ClinicalTrials.gov

Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multi-CAR T cell therapy targeting different AML surface antigens in patients with relapsed or refractory acute myeloid leukemia (AML). Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.

Official title: Multi-center Phase I/II Clinical Trial of Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Key Details

Gender

All

Age Range

2 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2025-07-15

Completion Date

2028-12-31

Last Updated

2026-06-23

Healthy Volunteers

No

Interventions

BIOLOGICAL

Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells

Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells

Locations (1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China